Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial -

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial
Information type: Randomised controlled trials
Source: Journal of Clinical Oncology
Specialities: Cancers | Haematological disorders
Summary
Results from this study (n=263; median follow-up 40.6 months) show that the advantages of ATRA-ATO over ATRA-CHT increase over time and that there is greater and more sustained antileukaemic efficacy of ATO-ATRA compared with ATRA-CHT in low- and intermediate-risk APL.
UKMi comment
Eligible patients were adults between 18 - 71 years of age with newly diagnosed, low- or intermediate-risk Acute Promyelocytic Leukemia (APL). Overall, 276 patients were randomly assigned to receive ATRA-ATO (all-trans-retinoic acid and arsenic trioxide or ATRA-CHT (all-trans-retinoic acid and chemotherapy).
Related links: